A Phase 1 interventional study of SR-878 in Rheumatoid Arthritis, sponsored by SciRhom GmbH. Recruiting at 4 sites in 3 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by SciRhom GmbH · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Arthritis, Rheumatoid with a site in Romania — 4 open to participants now, 8 under way, 1 of them phase 3. Arthritis, Rheumatoid · Romania.
Among the 115 studies in Arthritis, Rheumatoid with a site in Romania, this one is the 107th largest by planned enrollment of the 110 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 1, and was the 115th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 115 studies in Arthritis, Rheumatoid with a site in Romania are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Romania, Australia, Belgium and 8 more countries
Ages 18–75
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in Romania, United States, Australia and 7 more countries
Ages 18+
Artiva Biotherapeutics, Inc. · Sites in Romania, United States, Brazil and 8 more countries
Ages 18+
A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 52 · Phase 3 47 · Phase 4 7
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 27 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 371 across the 110 interventional studies, 505 across the 5 observational. Of the 107 that completed or were terminated, 77 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 115 have an industry lead sponsor. The 10 most frequent:
SciRhom GmbH is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
SciRhom GmbH has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
1 of the studies in Arthritis, Rheumatoid with a site in Romania that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06754462Immunovant Sciences GmbHA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 115 studies in Arthritis, Rheumatoid with a site in Romania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SR-878 is a newly developed medicine that aims to treat autoimmune disorders. It inhibits a protein (iRhom2), that regulates enzymes that are involved in the production of cytokines (small proteins that are crucial in controlling the activity of immune system cells). The aim of this clinical trial is to find a suitable safe and effective SR-878 dose for patients with rheumatoid arthritis. The study will include a screening period, an inpatient treatment period, and an outpatient follow-up period. The study duration for an individual participant is up to 113 days (about 16 weeks).
Rationale: SR-878 is an investigational medicine that targets a specific protein, called iRhom2, which is involved in inflammation in autoimmune diseases like rheumatic arthritis (RA). SR 878 blocks multiple inflammatory pathways without affecting normal body functions such as skin and gut barrier protection. This could offer broader anti-inflammatory effects with fewer side effects compared to existing therapies that block only one pathway. In a previous study with healthy volunteers, SR-878 caused a temporary increase in inflammation markers in the blood. Because this was completely unexpected, the study was stopped early. However, animal studies showed that this reaction did not occur in animals already suffering from an inflammatory condition like RA. Therefore, this new study is testing SR-878 directly in RA patients, to see if it is safe and to find the right dose to use in future studies.
Main objective: To see if SR-878 is safe and well tolerated in RA patients and to find the safest effective dose.
Additional objectives: To understand how the drug is absorbed, distributed, and cleared from the body, assess blood biomarkers (markers that indicate how the drug acts in the body), monitor additional safety parameters, and whether the body develops any immune reaction to it.
Study endpoints: The main endpoints include the percentage of patients who experienced adverse events during the study, including serious events, events linked to SR-878, and events which were so severe that the treatment dose had to be reduced or stopped. Further endpoints assess how long the drug stays in the body, how much of it is present in the blood over time (up to Day 85 and beyond), and the highest level of the drug found in the blood by Day 85. The percentage of patients who have important changes in laboratory values, electrocardiograms (ECGs), and vital signs (blood pressure, pulse and temperature) will also be evaluated as well as changes in blood biomarkers. And finally, the percentage of patients who develop an immune reaction against SR-878 will be assessed.
Study design: The study consists of a screening period (up to 28 days prior to treatment), an inpatient treatment period (3 days), and a follow-up of 82 days, thus, each patient will be in the study for up to 113 days.
Study population: Adults (18 to 60 years) diagnosed with active RA for at least 3 months who have tried and not responded well to at least one approved standard RA medication will be included. Patients must have used a molecule called methotrexate at a stable dose for at least 4 weeks before study start and must use that dose during the entire study. Individuals with any contraindication for SR-878, a diagnosis of other autoimmune diseases, active infections, or arthritis, using certain RA medications including so-called biologic treatments like tumor necrosis factor alpha blockers or interleukin-6 blockers, or with a medical history that could increase their risk during the study will not be included.
Methodology: This is a single dose escalation study, meaning that patients will receive one intravenous infusion of SR-878 at increasing doses to find the highest safe dose. Up to 9 different doses are planned to be tested. The gradual dose increases from one dose group to the next will be decided after a safety evaluation committee has carefully reviewed all data from previously treated patients, and no signals of concern had been observed. It starts with one patient at the lowest dose, then continues with groups of three patients per dose level. In addition, within a dose group, a patient will only be treated if the previous patient had no safety problems within 72 hours of dosing. Up to 27 patients may be included. Eligibility of patients will be assessed at a screening visit. Eligible patients will receive their SR-878 infusion on Day 1 and be hospitalized for at least 72 hours to closely monitor safety. After discharge from hospital patients will be further followed up at several clinic visits till the end of the study (Day 85).
Study-related procedures Screening: Written informed consent prior to any study-specific procedures, questions about demography, medical history, medication history, and on how patients assess disease activity (on a visual scale of 0 to 10), check of swollen and tender joints, physical examination which includes height and weight, ECG, vital signs, clinical laboratory tests, confirmation of RA diagnosis, recording of adverse events.
Treatment and follow-up: Some of the same assessments performed at Screening, infusion of SR-878, blood draws to measure SR-878 in the blood, safety laboratory, biomarkers (markers that indicate how the study medication acts in the body), and immune reaction, urine collections, recording of adverse events, and of new or changed medications.
Intervention: single infusion of SR-878 over 1 hour; patients are asked to continue methotrexate during the entire study at the dose already used 4 weeks before study start.
Ethical considerations: The study will be performed in accordance with the applicable version of the Declaration of Helsinki and in line with appropriate national regulations.
Risks: In a previous clinical study that tested SR-878 in 13 healthy people, most people with adverse events had mild events like cold symptoms, sore throat, headaches, and nausea. A few showed increased blood levels of an inflammatory marker (C-reactive protein), and one person had a pro inflammatory reaction called CRS (see above). CRS occur with different severities, and the reaction in this person belonged to the lowest severity grade, Grade 1 (the scale ranges from 1-5). As with other similar treatments, SR-878 may cause allergic reactions ranging from mild rashes to serious breathing issues and life-threatening reactions. To prevent this, SR-878 is given very slowly. If this happens anyway, emergency medications and equipment are readily available at the site. There is also a chance that it could increase the risk of infections and because this is a new drug, there may be unknown side effects. To protect patients a safety committee regularly reviews data and can stop the study if necessary.
Benefits: This study might help find a new and better treatment for RA. While patients may not directly benefit, the knowledge gained could help many others in the future.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women must not be pregnant or breastfeeding and
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
solution for infusion, administered intravenously
Drug: SR-878
Solution for infusion, administered intravenously
The number of participants with treatment-emergent adverse events (TEAEs), serious adverse events and related TEAEs
Proportion of participants with treatment-emergent adverse events (TEAEs), serious adverse events and related TEAEs
Time frame: Day 1 until day 85
Dose-limiting toxicities
The number of participants with dose-limiting toxicities (DLTs)
Time frame: Day 1 until day 85
Maximum tolerated dose
Determination of the maximum tolerated dose (MTD)
Time frame: Day 1 until day 85
To determine the pharmacokinetics (PK) as measured by t1/2
To determine the pharmacokinetics (PK) of a single dose of SR-878 as measured by the terminal half-life (t1/2) of SR-878.
Time frame: Day 1 until day 85
To determine the pharmacokinetics (PK) as measured by the area under the serum concentration-time curve (AUC0-85)
To determine the pharmacokinetics (PK) of a single dose of SR-878 as measured by the area under the serum concentration versus time curve (AUC) from time 0 to Day 85 (AUC0-85).
Time frame: Day 1 to day 85
To determine the pharmacokinetics (PK) as measured by the area under the serum concentration- time curve (AUC0-inf).
To determine the pharmacokinetics (PK) of a single dose of SR-878 as measured by the concentration versus time curve (AUC) extrapolated to infinity (AUC0-inf).
Time frame: Day 1 until day 85
To determine the pharmacokinetics (PK) as measured by the area under the serum concentration- time curve (AUC0-last).
To determine the pharmacokinetics (PK) of a single dose of SR-878 as measured by the concentration versus time curve (AUC) to the time of the last measurable concentration (AUC0-last).
Time frame: Day 1 until day 85
To determine the pharmacokinetics (PK) as measured by Cmax.
To determine the pharmacokinetics (PK) of a single dose of SR-878 as measured by the maximum concentration of SR-878 in blood serum (Cmax).
Time frame: Day 1 until day 85
To determine the pharmacokinetics (PK) as measured by tmax
To determine the pharmacokinetics (PK) of a single dose of SR-878 as measured by the time to the last measurable concentration of SR-878 (tmax).
Time frame: Day 1 until day 85
To determine the pharmacokinetics (PK) as measured by the total CL
To determine the pharmacokinetics (PK) of a single dose of SR-878 as measured by the total clearance (CL) of SR-878.
Time frame: Day 1 until day 85
To determine the pharmacokinetics (PK) as measured by the Vz
To determine the pharmacokinetics (PK) of a single dose of SR-878 as measured by the volume of distribution (Vz).
Time frame: Day 1 until day 85
To determine the pharmacokinetics (PK) as measured by t last
To determine the pharmacokinetics (PK) of a single dose of SR-878 as measured by the time of the last measurable concentration (t last).
Time frame: Day 1 until 85
To determine the proportion of participants with clinically relevant abnormal changes
To determine the proportion of participants with clinically relevant abnormal changes (assessed by the investigator) in clinical laboratory, electrocardiogram (ECG), vital signs
Time frame: Day 1 until day 85
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Feb 2028, 22 months after the start.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 22 months is above that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SciRhom GmbH